Approval of Phase I/II Clinical Trial of ATG-016 (Eltanexor), ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SHANGHAI and HONG KONG, Nov. 26, 2020 /PRNewswire-AsiaNet/ -- Antengene Corporation Limited ("Antengene", HKSE stock code: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-inclass therapeutics in hematology and...
Authors: LATEST ASIANET NEWS RELEASES